CiMaas CEO Prof Gerard Bos was interviewed about the current and future directions for dendritic cell vaccines.
Topics discussed are the current projects within CiMaas and what the key challenges are for CiMaas facing the clinical translation of the DC vaccine technology. He explains his views why DC vaccines may have faced difficulties in the past but why he is optimistic about the new technology. He further elaborates on the challenges arisen business wise as the scientific hurdles to develop the NK cell technology have been overcome.
The whole interview appeared in Cell & Gene Therapy Insights 2020; 6(2), 247–253. DOI: 10.18609/cgti.2020.034 or can be downloaded from this link.